前梯度蛋白2(AGR2)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法)
ELISA Kit DIY Materials for Anterior Gradient 2 (AGR2)
GOB4; HAG2; XAG2; AG2; PDIA17; HPC8; Anterior Gradient Protein 2; Protein Disulfide Isomerase Family A,Member 17; Secreted cement gland protein XAG-2 homolog
- 編號KSC285Mu01
- 物種Mus musculus (Mouse，小鼠)相同的名稱，不同的物種。
- 試劑內(nèi)容包被抗體、檢測抗體、標(biāo)準(zhǔn)品、HRP標(biāo)記的鏈霉親和素、TMB底物、96孔板
- 可檢測樣本Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.
- 可適用原理雙抗夾心酶聯(lián)免疫吸附試驗法測抗原
- 可檢測范圍1.56-100ng/mL
- 可適靈敏度0.62ng/mL
- 應(yīng)用自己動手制作ELISA試劑盒的主要材料
- 下載英文說明書 中文說明書
- 規(guī)格96T*596T*1096T*2096T*5096T*100
- 價格¥ 7153¥ 11922¥ 21460¥ 41727¥ 71532
- 欲了解實際交易價格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
試劑盒中的抗體對前梯度蛋白2(AGR2)具有高靈敏度和高特異性，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
用法
1.用100μL每孔的工作濃度的包被抗體包被96孔板，4度孵育過夜或者37度孵育2小時；
2.洗板1次；
3.用200μL每孔的工作濃度的封閉液,37度孵育1.5小時；
4.洗板1次。酶標(biāo)板即可用于ELISA實驗，后續(xù)使用方法與ELISA同。
儲存
抗體，標(biāo)準(zhǔn)品和HRP標(biāo)記的鏈霉親和素在-20度保存，TMB需在4度保存，96孔板在室溫保存。所有組分保質(zhì)期為1年，試劑一旦開封，在4度保存時間為1個月。
配套試劑
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Mus musculus (Mouse，小鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPC285Mu01 | 前梯度蛋白2(AGR2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAC285Mu01 | 前梯度蛋白2(AGR2)多克隆抗體 | WB; IHC |
| LAC285Mu71 | 前梯度蛋白2(AGR2)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| SEC285Mu | 前梯度蛋白2(AGR2)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| KSC285Mu01 | 前梯度蛋白2(AGR2)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法) | 自己動手制作ELISA試劑盒的主要材料 |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Cancer Biomarkers | Serum AGR2 as an early diagnostic and postoperative prognostic biomarker of human lung adenocarcinoma[MetaPress: n7137r6271u54118] |
| Molecular & Cellular Proteomics | Integrated Proteomic Profiling of Cell Line Conditioned Media and Pancreatic Juice for the Identification of Pancreatic Cancer Biomarkers[PubMed: PMC3205865] |
| Prostate. | Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype[Pubmed: 22911164] |
| BMC Cancer. | Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9[Pubmed: 24007603] |
| Clinical Cancer Research | Validation of Biomarkers That Complement CA19.9 in Detecting Early Pancreatic Cancer[Pubmed:25239611] |
| PLoS One | AGR3 in Breast Cancer: Prognostic Impact and Suitable Serum-Based Biomarker for Early Cancer Detection[PubMed: 25875093] |
| Clinical Neurology and Neurosurgery | Serum AGR2 as a useful biomarker for pituitary adenomas[S0303846717300045] |
| Oncotarget | Identification, characterization and application of a new peptide against anterior gradient homolog 2 (AGR2)[Pubmed:29937991] |
| Int J Oncol | Anterior gradient protein 2 is a marker of tumor aggressiveness in breast cancer and favors chemotherapy?induced senescence escape[34913074] |
| International Journal of Cancer | Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancer[Pubmed:35689436] |